A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
A randomized controlled trial evaluated the MyPal eHealth platform’s impact on quality of life among patients with chronic lymphocytic leukemia and myelodysplastic syndromes, revealing significant...
Adults 66 years and older with CLL who began treatment with a Bruton’s tyrosine kinase inhibitor were more likely to discontinue early, require subsequent therapy, and experience hospitalization compared...
A phase 3 trial confirms that combining ibrutinib with venetoclax yields superior measurable residual disease clearance, progression-free survival, and overall survival in patients with chronic lymphocytic...
Patients with breast cancer and coexisting chronic lymphocytic leukemia (CLL) present with more advanced disease and poorer survival compared with those without CLL, according to the results of a...
Acalabrutinib demonstrated a significantly safer cardiovascular profile and lower mortality risk compared with chemoimmunotherapy in patients with chronic lymphocytic leukemia based on a large retrospective...
In their phase 3, open-label trial, Brown and colleagues set out to address the need for more effective first-line treatment strategies for fit patients with untreated CLL.
A recent phase 3 study found that venetoclax-obinutuzumab improves progression-free survival and quality of life compared with chlorambucil-obinutuzumab in patients with untreated chronic lymphocytic...
